Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Daver, Naval  [Clear All Filters]
2024
Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, et al. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, Dinardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma. 2024:1-6.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, Dinardo CD, Borthakur G, Loghavi S, Patel K, Tang G, et al. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. 2024.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, et al. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024;11(4):e287-e298.
2023
Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, et al. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia. 2023.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023.
Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, Dinardo CD, Daver N, Yilmaz M, Abbas HA, et al. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023.
Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, et al. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in Class Rearrangements. JCO Precis Oncol. 2023;7:e2200707.
Fan H, Wang F, Zeng A, Murison A, Tomczak K, Hao D, Jelloul FZahra, Wang B, Barrodia P, Liang S, et al. Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance. Commun Biol. 2023;6(1):765.
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, Kadia TM, Dinardo CD, Takahashi K, Loghavi S, et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023;13(1):53.
Tyagi A, Jaggupilli A, Ly S, Yuan B, El-Dana F, Hegde VL, Anand V, Kumar B, Puppala M, Yin Z, et al. TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia. 2023.
2022
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KHee, Kanagal-Shamanna R, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2022.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022;9(5):e350-e360.
2021
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, Dinardo CD, Takahashi K, Konopleva M, Pemmaraju N, et al. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021.
Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, et al. Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia. Am J Hematol. 2021.
Kadia TM, Ravandi F, Borthakur G, Konopleva M, Dinardo CD, Daver N, Pemmaraju N, Kanagal-Shamanna R, Wang X, Huang X, et al. Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol. 2021.
Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, Dinardo CD, Kadia TM, et al. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer. 2021.
Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, et al. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021.
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Shamanna RKanagal, Konopleva M, Jain N, Dinardo CD, Khouri R, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021.
2020
Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, et al. Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations. Am J Hematol. 2020.
Borthakur G, Zeng Z, Cortes JE, Chen H-C, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, et al. Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020.
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, et al. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. Am J Hematol. 2020.
Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, et al. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020.
2019
Srour SA, Saliba RM, Bittencourt MCb, Perez JMiguel Ram, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, et al. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol. 2019.
Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019.

Pages